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A b s t r a c t
Introduction: Transgenic mice overexpressing mutated NEBL, encoding the 
cardiac-specific Z-disk protein nebulette, develop severe cardiac phenotypes. 
Since cardiomyopathies are commonly familial and because mutations in 
a single gene may result in variable phenotypes, we tested the hypothesis 
that NEBL mutations are associated with cardiomyopathy.
Material and methods: We analyzed 389 patients, including cohorts of pa-
tients with dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy 
(HCM), and left ventricular non-compaction cardiomyopathy (LVNC). The 28 
coding exons of the NEBL gene were sequenced. Further bioinformatic anal-
ysis was used to distinguish variants.
Results: In total, we identified six very rare heterozygous missense mutations 
in NEBL in 7 different patients (frequency 1.8%) in highly conserved codons. 
The mutations were not detectable in 320 Caucasian sex-matched unrelated 
individuals without cardiomyopathy and 192 Caucasian sex-matched blood 
donors without heart disease. Known cardiomyopathy genes were excluded 
in these patients. The mutations p.H171R and p.I652L were found in 2 HCM 
patients. Further, p.Q581R and p.S747L were detected in 2 DCM patients, 
while the mutation p.A175T was identified independently in two unrelated 
patients with DCM. One LVNC patient carried the mutation p.P916L. All HCM 
and DCM related mutations were located in the nebulin-like repeats, do-
mains responsible for actin binding. Interestingly, the mutation associated 
with LVNC was located in the C-terminal serine-rich linker region. 
Conclusions: Our data suggest that NEBL mutations may cause various car-
diomyopathies. We herein describe the first NEBL mutations in HCM and 
LVNC. Our findings underline the notion that the cardiomyopathies are true 
allelic diseases. 
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Introduction
Cardiomyopathies are heterogeneous heart 
muscle diseases that commonly have a  genetic 
cause [1, 2]. Whereas hypertrophic cardiomyop-
athy (HCM) and left ventricular non-compaction 
cardiomyopathy (LVNC) are classified as genetic 
forms according to the American Heart Associa-
tion, dilated cardiomyopathy (DCM) is familial in 
about one third of patients. The heterogeneous 
nature of the cardiomyopathies can be seen at 
the clinical and the genetic level [1, 2]. In HCM, 
the known disease genes may account for genetic 
causation in only about 50–60% of patients [1, 2]. 
Presumably additional disease genes exist. Recent 
studies also changed our earlier view of HCM as 
a solely sarcomeric and DCM as a solely cytoskel-
etal disorder. It has been shown that considerable 
overlap of disease-causing genes exists between 
the main phenotypically distinct forms of cardio-
myopathy [3, 4]. Moreover, mutations in certain 
genes may cause very variable phenotypes [3, 4].
Mutations in Z-disk associated proteins have 
been linked to cardiomyopathy [2, 5]. The cardi-
ac-specific protein nebulette, encoded by NEBL, is 
a good candidate, since the protein aligns thin fila-
ments and connects them to the Z-disk. Nebulette 
belongs to the nebulin family of actin-binding 
proteins that are important in myofibrillogenesis 
[6, 7] and assembly of the Z-line [8]. Nebulette 
also interacts with filamin C [9], myopalladin [10], 
α-actinin 2 [7], and tropomyosin and troponin T 
[11, 12]. The key role of NEBL is further supported 
by the recent generation of transgenic mice over-
expressing NEBL mutations in the heart and show-
ing severe cardiac phenotypes [13]. 
We therefore selected NEBL as a  candidate 
gene in patients with cardiomyopathies and sys-
tematically analyzed the gene in three well-char-
acterized cohorts of patients with HCM, DCM, and 
LVNC.
Material and methods
Patients
We studied 389 unrelated cardiomyopathy pa-
tients with HCM, DCM, or LVNC of mostly Euro-
pean origin. The respective local institutional re-
view boards (IRB) in Berlin, Paris, Prague, Pecs and 
Padova approved the study and written informed 
consent was obtained from all participants. The 
genetic analysis was performed in Berlin (IRB vote 
number AA/3/01/32 for genetic analysis in cardio-
myopathy patients). The study protocol conforms 
to the ethical guidelines of the 1975 Declaration 
of Helsinki.
The HCM cohort comprised 217 patients. The 
patients were managed either in Paris (96 pa-
tients), in Padova (26 patients) or in Prague (95 pa- 
tients). The diagnosis of HCM was made accord-
ing to the established criteria as described by us 
in detail previously [14, 15]. The DCM cohort in-
cluded 148 patients. The patients were managed 
either in Paris (114 patients; 65 familial and 49 
sporadic) or in Berlin (34 familial patients). Diag-
nosis of DCM was made according to the estab-
lished criteria as used and described previously 
[16, 17]. The LVNC cohort comprised 24 patients 
managed in Pecs. Relatives of patients with 
identified mutation were recruited after the ini-
tial genetic analysis and subsequently selected 
from their families. Diagnosis of LVNC was based 
on the criteria proposed by Petersen et al. [18]. 
The control cohort A comprised 320 sex-matched 
unrelated individuals (European origin) without 
cardiomyopathy. The second control cohort B in-
cluded 192 sex-matched blood donors (European 
origin) without heart disease. Further information 
about the cohorts can be found in the Supplemen-
tal methods.
Genetic analysis
Genomic DNA was isolated using standard 
methods. Primer pairs were used to amplify the 
28 coding exons of NEBL with flanking intronic 
sequences according to Arimura et al. [19] based 
on the published sequence (GenBank accession 
number NM_006393.2). Polymerase chain reaction 
amplifications were performed using standard 
protocols (available on request). The amplicons 
were analyzed by direct sequencing using ABI Big 
Dye Terminator chemistry and run on an ABI 3100 
Avant device (Applied Biosystems, Darmstadt, Ger-
many) as per the manufacturer’s instructions. De-
tected variants in a sample were confirmed at least 
in two independent PCRs and sequencing runs. Se-
quencher software version 4.8 (Gene Codes, Ann 
Arbor, MI, USA) or PhredPhrap/Consed free Softs 
was used to facilitate data analysis and mutation 
identification followed by visual inspection of in-
dividual sequencing traces. Genetic variants were 
annotated according to the cDNA and protein ref-
erence sequence (Ensembl ID ENST00000377122 
and UniProtKB/Swiss-Prot O76041). 
We further analyzed the detected variants by 
checking the presence or absence of these vari-
ants in large population-based databases (dbSNP 
and Exome Sequencing Project/ESP5400 dataset) 
and the possible impact of the amino acid sub-
stitution. Further information about the bioinfor-
matic analysis can be found in the Supplemental 
Methods. Briefly, the significance of the identified 
variants was assessed by considering the con-
servation of the affected amino acid, the nature 
and location of the change, its rarity assessed in 
own controls and population-based datasets, and 
cosegregation in the family when available. 
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Results
NEBL mutations
We sequenced NEBL in 389 cardiomyopathy pa-
tients and identified 20 different genetic variants 
(Figure 1). Fourteen variants were detected in dif-
ferent frequencies (from 1% to 31%) and were re-
garded as polymorphisms (Figure 1 A and see also 
Supplemental results and Supplemental Table SI). 
In contrast, six variants were detected in 1 patient 
each: p.H171R, p.A175T, p.Q581R, p.I652L, p.S747L, 
and p.P916L (with the exception of p.A175L, which 
was detected in two unrelated patients) (Table I). 
These were regarded as possibly disease-associ-
ated mutations because of the following facts. All 
six were heterozygous missense mutations (Sup-
plemental Figure S1); none was detectable in 640 
control alleles. Two mutations were not annotat-
ed in dbSNP (p.H171R, p.Q581R); we deposited 
two (p.A175T, p.S747L) (Table I). The mutations 
p.I652L and p.P916L were subsequently annotated 
in dbSNP with low allelic frequencies of 0.3% and 
0.08%, respectively (Table I). While four mutations 
were absent from the ESP5400 dataset (European 
Americans), two (p.A175T and p.I652L) occurred at 
a very low frequency of < 0.01%. Five amino acid 
substitutions altered a non-conserved residue (the 
exception was p.I652L). Two independent muta-
tion analysis tools predicted damaging effects for 
the six mutations (either PolyPhen2 and/or Muta-
tion Taster; see Supplemental methods). 
Mutation p.P916L is located in the N-terminal 
serine-rich linker region; the other five mutations 
are located in the central nebulin-like repeats 
(NLRs). These are important actin-binding mod-
ules of the protein (Figure 1 B). Alignment of se-
quences surrounding mutations from different 
orthologs (from chimpanzee to fish) showed very 
high conservation of the residue through evolution 
for three mutations (p.H171R, p.I652L, p.S747L) to 
high conservation for the other three mutations 
(Figure 2 B). Alignment of the 23 NLRs showed 
that three mutations (p.Q581R, p.I652L, p.S747L) 
are located in or close to the two common con-
sensus motifs (PEIXRXK box and SDXXYK box) in 
these domains (Figure 2 A). The amino acids glu-
tamine (p.Q581R) and isoleucine (p.I652L) are also 
conserved in different nebulette NLRs. 
Mutations p.H171R and p.I652L were found in 
2 HCM patients. Further, the mutations p.Q581R 
and p.S747L were detected in 2 familial DCM pa-
tients, while the mutation p.A175T was detected 
Figure 1. Localization of the mutations and other variants in the nebulette gene and protein. A – Distribution of 
detected variants in NEBL. In the schematic diagram, gray blocks symbolize the 28 exons of the gene. Very rare 
variants (possible disease-associated mutations) are indicated as black arrows above their exonic location. Other 
more frequent synonymous and non-synonymous variants are indicated by small gray arrows below their exonic 
location. B – Localization of the identified mutations in the nebulette protein. In the schematic diagram, gray blocks  
symbolize different protein domains. Nebulette consists of an N-terminal acidic glutamic acid-rich domain, 23 cen-
tral nebulin-like repeats (NLR), a serine-rich linker domain, and a C-terminal Src homology 3 (SH3) domain. Binding 
partners and interactions are shown below. The six possible mutations identified by us are denoted by long black 
arrows above the diagram, whereas mutations identified by Purevjav et al. [13] are denoted by small black arrows 
below the diagram. Notably, some of the mutations are close together, e.g. affecting the same NLR in two cases 
(schematic representations and interactions according to [6, 8, 29])
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in 2 unrelated patients with DCM. One LVNC pa-
tient carried p.P916L. Overall, this occurrence has 
a frequency of 1.8% (7/389). Mutation screening 
performed previously on several other cardiomy-
opathy genes in these patients was negative (de-
tails see below). As commonly observed in cardio-
myopathy, the small size of the families and the 
age-related incomplete penetrance only allowed 
cosegregation analysis in the families. The pedi-
grees are shown in alphabetical order in Figure 3. 
The clinical data of these patients are summarized 
in Table II.
Clinical features in HCM
The symptomatic male patient (proband A: 
II-6 of family A) of Czech origin, carrier of muta-
tion p.H171R, had HCM since the age of 53 years. 
He presented with moderate hypertrophy includ-
ing an interventricular septal thickness (IVS) of 
18 mm and posterior wall thickness (PWT) of 13 mm. 
His sister (A: II-5), 56 years old, was a carrier of the 
mutation but showed no signs of HCM. All other 
family members were negative for the mutation 
and also showed no HCM. Individuals A: II-2, A: II-3, 
and A: II-4 showed IVS values of 11–12 mm; all 
were treated for arterial hypertension.
The Italian female patient (proband B: II-3 of 
family B), carrier of mutation p.I652L, was diag-
nosed with juvenile HCM with severe hypertro-
phy at the age of 14 years. She received an im-
plantable cardioverter defibrillator (ICD) because 
of ventricular tachycardia (further clinical data in 
the Supplemental Results and Supplemental Fig-
ure S2). Her mother (B: I-2), 69 years old, carried 
the mutation and showed mild septal hypertrophy. 
But she was operated on because of calcific aor-
tic stenosis and a bicuspid aortic valve. Her father 
(B: I-1), aged 74 years, demonstrated HCM with 
an age of onset at 60 years and later on devel-
oped hypertension but did not carry the mutation. 
Of note, her brother (B: II-2), aged 45 years and 
a non-carrier of the mutation, showed mild hyper-
trophy and was treated for hypertension for about 
20 years. The 3 children (B: III-1, B: III-2, and B: 
III-3), aged from 18 to 22 years and each of whom 
had normal values in echocardiography, also did 
not carry the mutation. Neither of the above fam-
ilies had mutations in sarcomeric HCM genes 
(analyzed by DNA resequencing array by us and 
coworkers [20]).
Clinical features in DCM
The 47-year-old German patient (proband II-4 
of family C), carrier of mutation p.A175T, had dis-
ease onset at the age of 45 years and had severe 
DCM with a strongly dilated left ventricle and poor 
LV function (EF 15%). ECG showed atrial fibrilla-
tion as well as non-sustained ventricular tachy-
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cardia; an ICD was implanted. His twin brother 
(C: II-3) is also a  carrier of the mutation and 
awaits heart transplantation (TX) because of se-
vere DCM. His female cousin (C: III-1) underwent 
TX because of DCM but was not available for ge-
netic analysis. The proband has two male children 
(C: III-2, 19 years old, and C: III-3, 23 years old) 
who carried the mutation but were as yet disease 
free. His father (C: I-4) died of heart failure. The 
symptomatic brother (C: II-6) showed a  mildly 
dilated heart. He was diagnosed with an alco-
hol-toxic form of DCM because of known long-
term excessive alcohol consumption and showed 
a negative genotype.
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Figure 2. Conservation of the identified possible mutations p.H171R, p.A175T, p.Q581R, p.I652L, p.S747L, and 
p.P916L. A – Alignment of the 23 copies of nebulin-like repeats (NLR) present in human nebulette (according to Mil-
levoi et al. [30]) with mutations p.H171R, p.A175T, p.Q581R, p.I652L, p.S747L (small boxes). The NLRs are modules 
of about 35 residues present in all members of the nebulin protein family. They are characterized by the sequence 
motif SDXXYK (open box). NLR 15 to 22 additionally share a conserved motif (PEIXRXK box at their N-termini). The 
mutations are located in or close to these consensus motifs. The amino acids glutamine (p.Q581R) and isoleucine 
(p.I652L) are also conserved in different nebulette NLRs (as shown by bold letters). B – Alignment of orthologs from 
16 different species (from mammals and birds to fish). The altered amino acid and flanking residues are displayed 
in single-letter code. Bold letters mean conservation. Mutated residue in the human sequence is underlined
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Figure 3. Pedigrees of the families. Squares indicate males, circles females. Open symbols represent unaffected 
subjects and solid symbols affected individuals according to clinical examinations; shaded symbols represent indi-
viduals with borderline status; question marks represent individuals with unknown status where no clinical data 
were available; and slanted bars represent deceased individuals. The presence or absence of an NEBL mutation  
is indicated by a “+” or “–” symbol, respectively. No such symbol indicates that no DNA was available for analysis. 
An arrow denotes the proband
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The German male patient (proband D: II-1 of 
family D), aged 52 years and carrier of mutation 
p.Q581R, had symptoms (including dizziness and 
dyspnea on exertion) since the age of 46. Holter 
ECG showed intermittent tachycardia. He has a di-
lated LV and borderline LV function (48%). His fa-
ther (D: I-1) died at the age of 52 years because 
of DCM. His 60-year-old brother (D: II-2) awaits 
TX. No DNA was available from either. The disease 
genes LMNA, MYH7, ACTC, DES, PLN, MLP, TNNC, 
TNNI were excluded in both probands of families 
C and D. 
The French female patient (proband E: II-1 of 
family E), carrier of mutation p.A175T, was di-
agnosed with DCM at the age of 48 years. She 
showed mild dilatation and diminished LV func-
tion (EF 40%). Proband E: II-1 has a sporadic form 
of DCM; no other family members were affected 
or were available for genetic analysis.
The French male patient (proband F: II-1 of 
family F), carrier of mutation S747L and of Syri-
an origin, showed disease onset at the age of 
49 years. He had severe dilatation and poor LV 
function with an EF of 35%. His father (F: I-1) died 
at the age of 63 years because of heart failure. No 
other family members were available for clinical 
and genetic examination. Important DCM disease 
genes (LMNA, MYH7, ACTC, DES, SGCD, TNNT2, 
PLN, MYPN, and the cardiospecific exon 16 of VCL) 
were excluded in both probands of family E and F. 
Clinical features in LVNC
The 47-year-old male patient of Hungarian or-
igin (proband G: II-1 of family G), carrier of muta-
tion p.P916L, has been treated because of DCM 
and heart failure since the age of 37 years. Echo-
cardiography suggested the presence of hypertra-
becularization in the apical region of the left ven-
tricle. Cardiac magnetic resonance imaging (MRI) 
confirmed LVNC as described in Supplemental re-
sults and Supplemental Figure S3. His 67-year-old 
mother (G: I-2) and his two children (G: III-1 and 
G: III-2), 25 and 19 years old, respectively, were 
negative for the mutation and were unaffected as 
shown by echo and/or MRI. The proband G: II-1 
had been analyzed previously for mutations in 
12 known cardiomyopathy genes as described 
by us [20], and no mutation was found in any of 
these genes. 
Discussion
We identified six novel heterozygous missense 
mutations in NEBL in seven different patients and 
their families. We excluded known cardiomyopa-
thy genes in these patients, particularly the most 
frequent HCM disease genes [14, 20]. Overall, our 
data are highly suggestive for disease causation, 
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Figure 4. Diagram of the overlap of disease genes causing four different cardiomyopathy forms. Thirty-seven genes 
have been described so far, of which 20 genes cause at least two different forms of cardiomyopathy. Underlined 
gene symbols encode Z-disk proteins. Of note, all seven Z-disk genes are involved in the pathogenesis of two dif-
ferent cardiomyopathy forms. Conclusively, we have described the Z-disk gene NEBL as possibly associated with 
HCM, DCM and LVNC in this study (data according to [1–4])
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although without definite proof because of the 
small size of most families. The presence of six 
different mutations in seven unrelated cardiomy-
opathy patients makes the possible explanation 
of rare polymorphisms highly unlikely. This in-
terpretation is confirmed by the absence of the 
mutations in a high number of ethnically matched 
control individuals. Despite the very low frequency 
of the mutations (< 1/1000 alleles), we detected 
the 175 variant in two independent patients from 
Germany and France. Exome Sequencing Project 
(ESP) and dbSNP datasets confirmed the rarity/
novelty of all mutations, which is a major criteri-
on for pathogenicity in cardiomyopathies with so 
many “private” mutations [1, 2, 4]. Norton et al. 
proposed using the ESP dataset as a new resource 
for guidance in DCM patients [21]. They found an 
allele frequency of 0.04% as a  conservative cut-
off point for pathogenic mutations based on their 
bioinformatic analysis of DCM mutations against 
the ESP dataset. Using the same approach for 
NEBL, all mutations found by us are below that 
threshold, confirming their extreme rarity (Table I). 
We are aware that a  non-synonymous muta-
tion causing a  genetic disease increases in evo-
lutionarily highly conserved sites [22]. The affect-
ed amino acids of the identified mutations were 
highly conserved in different species. Interesting-
ly, the conservation could be partially observed in 
nebulette itself. The mutations at codons 581 and 
652 showed this conservation also in the differ-
ent nebulin-like repeats (Figure 2 A). Furthermore, 
the changes were non-conservative; namely, they 
changed the properties of the residues such as 
polarity or size, indicating deleterious effects on 
protein structure.
The localization of the mutations in a  func-
tional protein domain underscores a  possible 
pathogenic effect. Notably, five of the identified 
mutations reside in the nebulin-like repeats, the 
basic functional units for actin binding. The sixth 
mutation (p.P916L) is located in the serine-rich 
linker domain responsible for cellular targeting in 
the Z-disk (as shown by Panaviene et al. [23]). The 
fact that transgenic animal models expressing hu-
man NEBL mutations generated by Purevjav et al. 
resembled a cardiomyopathic phenotype strongly 
enhances the confidence in our results [13]. Final-
ly, the NEBL gene that encodes the Z-disk protein, 
nebulette, is an excellent candidate gene to con-
tribute to heart muscle disease. The fact that NEBL 
is preferentially expressed in the heart makes 
such speculation more plausible. Furthermore, 
there are a  number of known cardiomyopathy 
disease genes encoding Z-disk proteins (Figure 4). 
This scheme is quite fitting for nebulette.
Purevjav et al. [13] drew attention to four 
missense mutations in NEBL (p.K60N, p.Q128R, 
p.G202R, p.A592E). These are also located in the 
nebulin-like repeats and are in close vicinity to five 
mutations identified by us affecting the same re-
peat domain in two cases (Figure 1 B). They found 
NEBL mutations in two newborn DCM patients 
(one with endocardial fibroelastosis) and two pa-
tients with DCM manifestation in adulthood [13]. 
We found mutations in familial as well as sporad-
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ic cases with DCM and additionally in cases with 
HCM or LVNC. Furthermore, we identified clinical 
manifestation of cardiomyopathy mostly in adult-
hood (the exception was one child with severe 
HCM). There seems to be a  possible relation to 
age as seen in the probands with NEBL mutations 
who have an age at diagnosis between 41 and 
53 years (Table II).
Relatives without cardiomyopathy often showed 
a  negative genotype, whereas pathological phe-
notypes co-segregated with an NEBL mutation 
(Figure 3). However, two individuals, C: III-2, 
19 years old, and C: III-3, 23 years old, from family 
C were mutation carriers without a cardiomyopa-
thy phenotype. This could be attributed to their 
young age, which is well known to be associated 
with a low probability of cardiomyopathy expres-
sion due to age-related penetrance [1, 4]. The un-
affected individual A: II-5, a mutation carrier and 
56 years old, may be explained by the fact that 
penetrance increases with age but remains less 
than 100%, as Watkins et al. stated in their review 
[4]. The clinical significance of the p.I652L variant 
in family B is puzzling. The mother (B: I-2) showing 
hypertrophy and aortic stenosis was a  carrier of 
the mutation. However, two relatives with some 
degree of hypertrophy did not carry the muta-
tion. While individual B: I-1 had an unequivocal 
HCM, individual B: II-2 showed mild hypertrophy 
and arterial hypertension and therefore may be 
regarded as a  likely phenocopy (i.e. masquerad-
ing as HCM). On the one hand, p.I652L is highly 
conserved in orthologs and NLRs and quite rare 
in patients and controls (0.01% according to ESP). 
On the other hand, it is the only conserved change 
predicted to be benign by PolyPhen2 and has an 
allelic frequency of 0.3% according to dbSNP. Tak-
en together, we would classify p.I652L as a variant 
of unknown significance.
We suggest that NEBL mutations may generate 
cardiomyopathy phenotypes. Thus we must pro-
pose mechanisms. Moncman and Wang showed 
that a  targeted disruption of nebulette expres-
sion in cardiomyocytes significantly altered myo-
fibril assembly and function [24]. Purevjav et al. 
validated the functional effects of four human 
NEBL missense mutations in detail [13]. They 
generated transgenic mice with cardiac-restricted 
overexpression of human wild-type and mutant 
nebulette, showing a  variety of phenotypes and 
severity in vivo ranging from embryonic lethal-
ity due to cardiac abnormalities to LV enlarge-
ment and diminished LV function at later stages 
[13]. Effects at the molecular/cellular level were 
changes in I-band and Z-disk composition and 
abnormal distribution of mutant nebulette under 
mechanical stretch. Their findings showed that 
NEBL mutations have strong but different effects 
on nebulette function itself and the function of 
interacting proteins depending on the location 
of the respective mutation. Ram and Blaxall con-
cluded that nebulette may play dual roles as both 
a structural protein of the Z-disk, and also – possi-
bly through its binding partners – as a regulatory 
protein of signaling pathways [25]. The findings of 
Purevjav et al. suggest that nebulette is required 
for normal sarcomere genesis and Z-disk stabiliza-
tion during development and adult function [13].
We were struck by the fact that nearly all Z-disk 
genes were associated with DCM as well as HCM, 
as Bos and Ackerman noted [26] (underlined genes 
in Figure 4). They pointed out that for Z-disk-me-
diated cardiomyopathies it is difficult to envision 
how divergent phenotypes emerge, especially be-
cause maladaptive dilatation seems a more plausi-
ble phenotypic response than maladaptive hyper-
trophy, given the role of the Z-disk as a sarcomeric 
stretch sensor and mechanoreceptor [26]. The di-
vergence in phenotypes may reflect the multiple 
roles of nebulette in modulating cardiomyocyte 
stretch-strain with specific structural/cytoskeletal 
modifications, as Ram and Blaxall proposed [25]. 
However, there is still a wide knowledge gap be-
tween the specific genetic cause and the mecha-
nism producing a  specific clinical phenotype [3]. 
A  complete understanding of how underlying 
mutation and resulting phenotype are connected 
is still pending for the cardiomyopathies. It is ob-
vious that the ultimate phenotype represents the 
sum of all the parts: genotype, mutant RNA and 
protein expression, further genetic variants, and 
epigenetic influences as well as environmental 
factors [3]. But we still lack integrated approaches 
that could elucidate the mechanisms.
There may be some caveats to the interpreta-
tion of the present study. First, it is limited by the 
fact that the families were too small to perform 
linkage analysis. Cosegregation analysis was pos-
sible in four families and produced inconclusive 
results in one of them. Second, no functional stud-
ies were performed. We were therefore cautious 
with the assignment of true disease causation [2, 
21, 27, 28]. However, considering the conserva-
tion of the affected amino acid, the nature and 
location of the change, its absence in controls and 
the general population, and the reported animal 
models of related mutations point to a  possible 
significance of five of the identified mutations (as 
we regard p.I652L as a variant of unknown signif-
icance). 
It was not possible to screen all known genes 
associated with cardiomyopathy; so we cannot 
exclude the possibility that the mutation carriers 
may be double heterozygotes. This is in particular 
true for DCM genes, whereas we excluded near-
ly all HCM genes. However, even greater patient 
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numbers may be necessary to draw more gener-
al conclusions about the frequency of NEBL mu-
tations in cardiomyopathy patients. Our purpose 
here was to draw attention to NEBL, a gene that 
we believe warrants much more multidisciplinary 
research attention.
In conclusion, our data strongly suggest that five 
different NEBL mutations are possibly associated 
with various cardiomyopathies. Already known for 
DCM, we herein describe the first possible NEBL 
mutations in HCM and LVNC. Our findings underline 
the notion that the cardiomyopathies are true allelic 
diseases. With regard to next generation sequenc-
ing methods, NEBL may be added to a set of cardio-
myopathy genes which now can be quickly analyzed 
in parallel with a target enrichment approach. 
Supplemental data
Supplemental data contain Supplemental 
methods, Supplemental results, Supplemental Ta-
ble SI and Supplemental Figures S1, S2, and S3.
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Patients
In total, 389 unrelated cardiomyopathy pa-
tients (HCM, DCM, or LVNC) were evaluated ac-
cording to the American Heart Association defini-
tions [1]. They were all of European origin (with 
the exception of the French DCM cohort with 93% 
Western Europeans). All cohorts were examined 
using a comparable protocol based on the medical 
history, physical examination, two-dimensional 
and M-mode echocardiography, and 12-lead elec-
trocardiogram (ECG), without knowledge of the 
genetic status. Holter ECG, heart catheterization, 
angiography, and cardiac magnetic resonance im-
aging (MRI) were performed in some patients as 
clinically indicated. Causes of heart disease such 
as coronary artery disease, myocarditis, severe 
arterial hypertension, and valvular heart disease 
were carefully excluded from the present study. 
All subjects agreed to participate in the study and 
gave written informed consent. The study was 
approved by the responsible local institutional re-
view boards in the respective centers.
The diagnosis of HCM was made according to 
the established criteria. Briefly, the major inclusion 
criterion was the presence of interventricular sep-
tal thickness (IVS) ≥ 13 mm (15 mm if sporadic, 
13 mm if familial) in the absence of other known 
causes of hypertrophy (such as hypertension and 
aortic stenosis) often accompanied by major ECG 
abnormalities such as negative T-waves, patholog-
ical Q-waves, and left ventricular hypertrophy.
Diagnosis of DCM was made according to the 
established criteria. The main criteria for DCM 
were defined as an echocardiographically mea-
sured left ventricular ejection fraction (EF) < 45% 
and left ventricular end-diastolic diameter (LVEDD) 
> 56 mm (or greater than the theoretical value ac-
cording to age and body surface) in the absence of 
coronary artery disease. The patients had no sys-
temic hypertension. Familial DCM was diagnosed 
if another affected relative had proven or highly 
suspected DCM according to the European guide-
lines of Mestroni et al. [2].
Diagnosis of LVNC was based on established cri-
teria. All included patients showed a thickened LV 
myocardial wall with a two-layered structure com-
prising a compact (C) epicardial layer and a non-
compacted (NC) endocardial layer of prominent 
trabeculations and deep intertrabecular recesses. 
The maximal end-diastolic ratio of noncompacted 
to compacted wall was > 2.3 measured by MRI. 
The patients had no systemic hypertension.
We used two established control cohorts [3]. 
The control cohort A  comprised 320 Caucasian 
sex-matched unrelated individuals without car-
diomyopathy (who had preserved EF > 55% and 
Supplemental Figure S1. DNA sequencing electropherograms demonstrating heterozygosity for the six detected 
NEBL mutations. The missense mutations are shown as two overlapping peaks (marked with an arrow). Codons 
are marked with gray blocks
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no ventricular dilatation and hypertrophy as 
shown by echocardiography and ventriculography 
and/or angiography). All of these individuals were 
older than 50 years (in order to exclude late onset 
cardiomyopathy). The second control cohort B in-
cluded 192 Caucasian sex-matched blood donors 
from the local blood transfusion service without 
heart disease. None of the control individuals was 
hypertensive. 
Genetic analysis
A bioinformatic approach for detected variants 
was used which was based on presence or ab-
sence of these in population-based databases. 
First, we searched dbSNP (build 135, at http://
www.ncbi.nlm.nih.gov/snp), which also includes 
data from the 1000 Genomes project. Second, we 
searched the Exome Variant Server (EVS) provid-
ed by the Exome Sequencing Project (ESP) of the 
National Heart, Lung and Blood Institute (http://
evs.gs.washington.edu/EVS/, Tennessen et al. 
[4]). The EVS data release ESP5400 is taken from 
5379 samples drawn from multiple ESP cohorts 
and represents the first data freeze of the ESP ex-
ome variant data (EVS release version: v.0.0.12). 
The ESP dataset includes exome data for 3510 
individuals of European descent, which matched 
our patients. Third, we performed mutation pre-
diction by the two most widely used analysis 
tools to predict the possible impact of an amino 
acid substitution. PolyPhen2 analysis was per-
formed through the portal http://genetics.bwh.
harvard.edu/pph2/ [5]. Mutation Taster analysis 
was performed through the portal http://www.
mutationtaster.org [6]. 
Supplemental results
Clinical features
Proband II-3 of family B, carrier of mutation 
p.I652L, had severe hypertrophy (IVS 32 mm, PWT 
16 mm) which progressed into thinning of the sep-
tum (IVS 26 mm), followed by dilatation (LVEDD 
from 43 to 62 mm) and reduction of EF (from 58% 
to 26%) over a period of about 20 years. Therefore, 
she underwent heart transplantation at the age of 
Supplemental Figure S2. Heart removed at transplantation of a HCM patient with NEBL mutation (proband B: II-2 
of family B). A – Apical transverse section of the heart showing dilatation of the left ventricular (LV) and thinning 
of the septum and ventricular free wall; whitish areas (arrows) are indicative of septal scarring. B – Long-axis LV 
section (atria missing due to transplantation). Subaortic outflow tract obstruction with endocardial fibrous plaque 
(arrow). C – Histology of right ventricle (RV) showing myocyte hypertrophy and disarray; hematoxylin eosin stain, 
160×. D – Histology of the septum with extensive replacement fibrosis and myocyte vacuolization; Azan-Mallory 
stain 200×
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Supplemental Table SI. Detected variants in the coding region of NEBL
DNA change AA change Exon Variant Known/novel dbSNP ID Reference
c.109T>C p.L37L 2 sSNP Known rs140734883 –
c.180G>C p.K60N 3 nsSNP Known rs41277374 Purevjav et al. (2010)
c.191A>G p.K64R 3 nsSNP Known rs71578975 –
c.489T>C p.Y163Y 6 sSNP Known rs141153708 –
c.604G>A p.G202R 7 nsSNP Known rs137973321 Purevjav et al. (2010)
c.1051A>G p.M351V 11 nsSNP Known rs4025981 Arimura et al. (2000)
c.1132G>C p.D378H 12 nsSNP Known rs41277370 –
c.1672A>C p.R558R 17 sSNP Novel – –
c.1861A>G p.I621V 18 nsSNP Known rs79718972 –
c.1962T>A p.N654K 19 nsSNP Known rs4748728 Arimura et al. (2000)
c.2031G>A p.R677R 20 sSNP Known rs1006363 –
c.2182A>G p.T728A 22 nsSNP Known rs71535732 Arimura et al. (2000)
c.2654C>T p.S885F 26 nsSNP Known rs143584663 –
c.2997A>G p.T999T 28 sSNP Known rs2296614 –
AA – amino acid, sSNP – synonymous SNP, nsSNP – non-synonymous SNP, dbSNP ID – SNP database (build 135) identifier.
46 years. This “end-stage” HCM patient showed 
LV chamber dilatation with diffuse transmural fi-
brous replacement in the ventricular septum and 
LV free wall (Supplemental Figures S2A and S2B). 
Histopathological features of HCM such as myo-
cyte hypertrophy and myocyte disarray were pres-
ent in her heart (Supplemental Figures S2C) as 
well as extensive replacement fibrosis  and myo-
cyte vacuolization (Supporting Figure S2D).
Cardiac MRI of proband II-1 of family G, carrier 
of mutation p.P916L, revealed LVNC affecting the 
entire apical region as well as the mid-segments 
of the lateral and anterolateral wall (7 segments 
in 17-segment model) (Supplemental Figure S3). 
The maximal NC/C ratio was 3.8. The left ventri-
cle was severely dilated (LVEDD 66 mm, LVESD 
53 mm), with severely reduced EF (30%). Due to 
multiple episodes of non-sustained ventricular 
tachycardia, an ICD was implanted at the age of 
43 years.
Further detected variants in NEBL 
We identified 14 single nucleotide variants 
including five synonymous and nine non-synon-
ymous variants (Supplemental Table SI). All of 
these were detected in the cardiomyopathy co-
horts in different frequencies (from 1% to 31%) 
and were represented in dbSNP except for one. 
Two of these variants, p.K60N and p.G202R, were 
recently described by Purevjav et al. in two adult 
DCM patients [7]. To validate our results, we ana-
lyzed a second independent control group (cohort 
B) in addition to control cohort A (1024 control al-
leles in total). We detected the variant p.K60N in 
five HCM patients (frequency 2.3%). Subsequent 
evaluation in the two control cohorts A and B re-
vealed p.K60N in 14 subjects (frequency 2.7%) 
including one with homozygous genotype. The 
variant p.G202R was identified in one HCM pa-
tient (frequency 0.5%). Analysis of the two con-
trol cohorts revealed four individuals carrying the 
heterozygous variant (frequency 0.8%). A  search 
of the ESP data showed that p.K60N and p.G202R 
are present in allele frequencies of 0.31% and 
1.08%, respectively.
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Supplemental Figure S3. Magnetic resonance imaging of the heart of the LVNC patient with NEBL mutation (pro-
band G:II-1 of family G). ECG retrogated SSFP movie sequence (trufi) was used to assess ventricular function on 
a 1.5T Siemens Avanto instrument. A – Diastolic four-chamber view shows significant LVNC (arrow) affecting the 
entire apical region as well as the mid-segment of the lateral wall. B – Short axis images show significant LVNC 
(arrows) affecting the entire apical region as well as the mid-segments of the lateral and anterolateral wall 
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